Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ART27.13

Next Previous
Drug Profile

ART27.13

Alternative Names: ART-2713; AZD-1940; NEO-1940

Latest Information Update: 25 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; NEOMED; Pfizer
  • Developer adMare BioInnovations; Artelo Biosciences; AstraZeneca
  • Class Alkanes; Analgesics; Antiemetics; Appetite stimulants; Benzimidazoles; Cannabinoids; Cyclohexanes; Fluorinated hydrocarbons; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anorexia; Open-angle glaucoma
  • Preclinical Cachexia; Neuropathic pain
  • Discontinued Cancer pain; Nausea and vomiting; Pain

Most Recent Events

  • 20 Aug 2026 Artelo Biosciences receives patent allowance for ART27.13 in Japan
  • 17 Aug 2026 Artelo Biosciences receives patent allowance for ART27.13 in USA
  • 10 Aug 2026 Phase-II clinical trials in Open-angle glaucoma (Treatment-experienced) in United Kingdom (PO) (ISRCTN10996483)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top